1 incredible growth stock I can’t find on the FTSE 100

The FTSE 100 offers us a lot of interesting investment opportunities, but there’s not much in the way of traditional growth stocks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I invest in FTSE 100-listed stocks, but when I want greater exposure to growth, I tend to look to the US markets.

Obviously, building the perfect portfolio for my age group and risk profile requires me to pick my stocks carefully. And by investing in US markets, I have much greater choice when it comes to growth-oriented investments.

So here’s one incredible growth stock that’s actually dipped in recent weeks. It’s gene therapy leader CRISPR Therapeutics (NASDAQ:CRSP).

What is gene editing?

Gene editing is a novel technology that offers us the opportunity to treat a range of illnesses that were previously untreatable and gives us a new tool to tackle conditions like cancer and heart disease.

CRISPR Therapeutics uses a gene-editing technology with the name’s acronym standing for ‘clustered regularly interspaced short palindromic repeats‘.

Inspired by bacteria’s built-in editing tools, the technology used by this Swiss firm allows scientists to design custom-guide sequences that precisely target specific regions of DNA.

It’s incredibly complex, utilising RNA and a Cas9 — CRISPR-associated protein 9. The RNA’s job is to recognise the target DNA and Cas9 snips it at the right juncture.

After the snip’s been made, scientists can then add or remove bits of genetic material, and the cell’s repair machinery takes over, patching things up.

There are still plenty of things we don’t know about CRISPR treatments, but trial data suggests it’s safe and effective. CRISPR Therapeutics isn’t the only company using gene editing therapies, but it’s the first to market.

It’s also worth noting that peer Beam Therapeutics uses something called base editing technology. It’s more nascent, but supposedly safer as it only modifies a single chemical unit (a base) within the DNA code.

First to market

Early CRISPR treatments have targeted sickle cell disease (SCD) and beta-thalassemia. Both SCD and beta-thalassemia are caused by mutations in a single gene.

This makes them well-suited for CRISPR’s function of editing specific DNA sequences. In fact, SCD is caused by a single, well-defined and traceable mutation in the beta-globin gene.

And CRISPR Therapeutics’s first treatment, which it owns in partnerships with Vertex (40%/CRISPR and 60%/Vertex) does indeed treat these two illnesses.

Understanding the exact commercial value of this treatment isn’t easy. It’s received regulatory approval in the UK, US, EU, and Saudi, among other places — first-to-market along with bluebird bio — but the next step is getting healthcare providers to pay for it.

I’ve seen estimates suggesting the treatment, priced at $2.2m a patient, could be worth around $70.4bn based on an initial patient cohort of 32,000 sufferers.

The company recently received a boost on reports that the US Centers for Medicare and Medicaid Services could received enhanced payments under proposed guidelines in an effort to encourage more innovation in the space.

The drawback is that we’re not sure whether these $2.2m treatments will cure sufferers for life. That said, the data has been very positive to date.

The bottom line

I’m already an investor in CRISPR Therapeutics, but I’m tempted to increase my position. The stock’s dipped because of an absence of news, rather than any negative reports.

In addition to its SCD and beta-thalassemia treatments, CRISPR Therapeutics has an attractive and innovative pipeline that could save lives and deliver commercial value in the future.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has positions in CRISPR Therapeutics. The Motley Fool UK has recommended CRISPR Therapeutics. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£10,000 invested in Barclays shares 1 month ago is now worth…

Barclays shares have carried on where they left off in 2024, by climbing far faster than the FTSE 100. Harvey…

Read more »

Investing Articles

I’ve been watching the easyJet share price like a hawk. Here’s what it did last week

Harvey Jones can't take his eyes off the easyJet share price. He thinks it looks good value and ready to…

Read more »

Investing Articles

A £10,000 investment in Nvidia stock 6 months ago is now worth…

Nvidia stock's shown a lot of volatility for a mega-cap company in recent weeks. Dr James Fox explores how an…

Read more »

Investing Articles

4 reasons Ferrari could continue to be a stock market winner

The global luxury goods market may have struggled in recent years, but you wouldn’t guess that from Ferrari’s soaring stock.

Read more »

Investing Articles

5 perfect starter stocks to consider for a Stocks and Shares ISA in 2025

Wondering which shares to buy for a newly opened Stocks and Shares ISA? Our writer thinks these five investments are…

Read more »

Row of terrace houses.
Investing Articles

Thinking about buy-to-let? Consider these UK stocks instead

Owning UK property stocks could be a better way to invest in buy-to-let, though there are drawbacks. Royston Wild explains.

Read more »

Investing Articles

Here’s a plan to target £7,500 a month in passive income

This writer outlines a roadmap that someone could consider taking to try and aim for a substantial future passive income…

Read more »

Young female hand showing five fingers.
Investing Articles

5 FTSE 250 stocks Fools are backing for promotion to the FTSE 100 this year

Can Vistry make an imminent return from the FTSE 250? One Fool thinks so -- read on to find out…

Read more »